Introduction
Zonisamide is a structurally novel antiepilepsy drug (AED) with a broad spectrum of antiseizure activity. At the cellular level, there are at least two mechanisms of action, blockade of sustained firing of voltage-sensitive sodium channels and reduction in voltage-dependent T-type calcium channel currents. 1, 2 Zonisamide has been available in Japan since 1989, where it is widely used both as monotherapy and adjunctive therapy for various seizure types and syndromes in adults and children. In the United States, clinical trials of zonisamide began in the early 1980s. These studies provided clear evidence of zonisamide's promise as an effective adjunctive therapy for refractory partial seizures. Leppik et al. 3 observed a 52% reduction in seizure frequency in a historical-control, open-label, multicenter study. However, development of kidney stones in 3.7% of patients enrolled in this study led to the temporary termination of US development efforts. Testing resumed in the 1990s, and S60 E. This article summarizes findings from key US clinical trials carried out since 1984. 4, 5 A total of 810 patients have participated in these trials. The focus is on findings from placebo-controlled and open-label studies that have examined the drug's short-and long-term efficacy and safety for the treatment of refractory partial seizures. Tables 1 and 2 provide brief descriptions of key US clinical trials. All study designs included a dose-titration phase, usually 4 weeks in length, with the exception of study 922 US, which used 4-and 8-week titration schedules. In long-term extension studies, patients who had been on zonisamide treatment in a preceding short-term study initially continued at the same dose; then, dose adjustments were allowed to a maximum of 600 mg per day or to a target range of serum levels of 20-30 g/mL, but not to exceed 40 g/mL.
Method
In all studies, primary and secondary efficacy variables were median percentage change from baseline in seizure frequency and percentage of responders, respectively. A responder was defined as any patient who experienced ≥50% reduction from baseline seizure frequency. In all studies except study 921, baseline seizure frequencies were determined based upon seizure diaries and communication between investigators and patients or caregivers. In study 921, baseline seizure frequencies were determined more informally, based on patient or investigator recall. For long-term studies 912 US EXT and 912 EU EXT, changes in seizure frequencies and response rates were calculated using baseline seizure frequencies from the preceding short-term study.
The safety of zonisamide was assessed primarily in terms of treatment-emergent adverse events. Results from clinical laboratory evaluations and other tests, including renal ultrasonograms, were also taken into consideration. In some studies, data on serum levels of zonisamide were analyzed to identify possible correlations with efficacy measures and adverse effects.
Results

Short-term, placebo-controlled studies
Patient demographics
Patients in these studies ranged in age from 12 to 79 years. In placebo-controlled trials, patients in placebo and treatment groups were generally comparable in age, weight, height, race, seizure type, and baseline seizure frequency. In study 912 US, the number of male patients enrolled was considerably higher than that of females, but statistical analyses revealed no significant effect of gender on efficacy. 
Efficacy results
Efficacy findings from the three placebo-controlled studies are summarized in Figs. 1 and 2. Fig. 1 shows that patients who took zonisamide at dosages of 400-600 mg per day as an add-on to existing AEDs experienced a median reduction in all partial seizures of 27.2, 29.6, and 40.5% for studies 912 EU, 912 US, and 922 US, respectively. These values differed significantly from placebo values of −1.1% (912 EU; P < 0.05), −3.3% (912 US; P < 0.0001), and 9.0% (922 US; P = 0.0082). Assessment of the percentage of responders also demonstrated that Figure 1 Reduction in seizure frequency with zonisamide treatment in placebo-controlled studies. All partial seizures; zonisamide doses 400-600 mg per day. * The differences from placebo were statistically significant (P < 0.05).
zonisamide effectively reduced seizures relative to placebo (Fig. 2) .
Protocols for the three placebo-controlled studies differed in several ways, including the manner in which zonisamide was introduced. In study 912 US and 912 EU, patients who received zonisamide were given the drug at dosages of 100 mg per day the first week, 200 mg per day the second week, and 400 mg per day for weeks 3 and 4. After week 4, dosages could be adjusted as necessary to a maximum dosage of 20 mg/kg per day or to a maximum plasma level of 40 g/mL. In contrast, Figure 2 Percentage responders to zonisamide in short-term studies. Responder rates for all partial seizures; zonisamide doses 400-600 mg per day. * The differences from placebo were statistically significant (P < 0.05). patients in study 922 US received zonisamide in one of three dose escalation regimens. One group received 100 mg per day for 5 weeks, 200 mg per day for 1 week, 300 mg per day for 1 week, and 400 mg per day for 13 weeks. The second group received 100 mg per day for 1 week, 200 mg per day for 5 weeks, 300 mg per day for 1 week, and 400 mg per day for 13 weeks. The third group received placebo for 12 weeks, 100 mg per day for 1 week, 200 mg per day for 1 week, 300 mg per day for 1 week, and 400 mg per day for 5 weeks. This design permitted examination of efficacy at low zonisamide doses during the titration phase of the study. Study 922 US results showed that a significant therapeutic benefit was obtained even at 100 mg per day (24.7% reduction in partial seizure frequency with zonisamide compared to 8.3% reduction with placebo; P = 0.0389) (Fig. 3) . Results at 200 mg per day also showed significant improvement relative to placebo, 23% reduction versus 4% for placebo (P = 0.0023) (Fig. 3) .
Safety and tolerability results
Zonisamide was well tolerated in the short-term, placebo-controlled studies. Adverse events most often involved effects on the nervous system; those reported most frequently by patients in the two US placebo-controlled trials are shown in Table 3 . In considering these results, it is important to note that all patients were receiving at least one additional AED in addition to study drug or placebo, and about half were receiving two. Moreover, adverse events were notably higher in most categories when titration was more rapid (as in study 912 US), than when titration was slower (as in study 922 US). With slower titration, only dizziness, somnolence, anorexia, accidental injury, headache, infection, and nausea occurred in ≥10% of patients in the zonisamide group (Table 3) , and only the incidence of anorexia was significantly higher than in the placebo group. The frequency of adverse events in study 922 US declined during weeks 13-20 of treatment, suggesting that patients develop tolerance to these adverse events. Clinical laboratory evaluations revealed no changes of clinical consequence.
Few adverse events were classified as serious. Among the serious adverse events, few were considered zonisamide-related or possibly zonisamide-related; most commonly rash, increased seizures, and kidney stones. Four patients in 922 US had possible renal calculi during the 20-week treatment period. These were all suspected by ultrasound, none were symptomatic, and zonisamide was not discontinued in any patient because of a suspicious ultrasound finding. No kidney stones occurred among patients in study 912 US or 912 EU.
Serum levels of zonisamide
Serum levels during study 922 US bore a roughly linear relationship to dosage. Dosages of 200 mg per day produced mean serum concentrations that were approximately twice that of patients taking 100 mg per day (6.94 g/mL versus 3.64 g/mL), but mean serum concentrations at dosages of ≥400 mg per day were in the range of 16.32-21.77 g/mL. The slightly lower than expected concentrations at lower dosages may have been due to erythrocyte binding of zonisamide, a less significant factor at the 400 mg dose. Reduction in partial seizure frequency at the lower zonisamide dosages, 100 and 200 mg per day, did not correlate with increasing serum concentrations, with 3.64 g/mL associated with a median reduction of 24.7%, and 6.94 g/mL associated with a median reduction of 23.0%. The 400 mg per day dosage, however, produced a median reduction of 40.5%. In studies 912 US and 922 US, no differences were observed when serum zonisamide levels among responders were compared with those of nonresponders. This phenomenon has been observed with studies of other AEDs and probably reflects biological differences in the severity of epilepsy between patients rather than a true lack of correlation between dose and response for individual patients. No clear relationship was observed between serum concentrations and the percentage of patients experiencing adverse events.
Long-term studies
Patient demographics
Patients in studies 912 US EXT, 912 EU EXT, 920, and 921 ranged in age from 12 to 79 years. Percentages of males and females in each study were approximately equal, with the exception of 912 US EXT, which included about twice as many males as females. The median baseline frequency of all partial seizures ranged from 7.4 per month (921) to 9.8 per month (912 US EXT).
Efficacy findings
In the long-term studies, the median percentage reduction from baseline in all partial seizures ranged from 13.9% (921) to 50.1% (912 US EXT) (Fig. 4) . The proportion of patients who were classified as responders ranged from 28.1% (921) to 55% (912 EU EXT).
Comparison of patient responses in 912 US and 912 EU with data from their respective extension studies shows that efficacy was maintained or possibly improved over time. For example, median reductions for all partial seizures for 912 US and 912 EU were 29.6 and 27.2%, respectively; with long-term treatment in study 912 US EXT and 912 EU EXT, median reductions were 50.1 and 45.4%, respectively. Studies 920 and 921 also compared responses during the initial weeks of treatment and over longer intervals (up to 24 months). In 920, short-term treatment (weeks 5-16) yielded a 35.8% reduction in all partial seizures; with long-term treatment (2-24 months), the overall reduction was 37.9%. In study 921, zonisamide treatment produced an 11.2% reduction in partial seizures over weeks 5-24 and a 13.9% reduction over months 7-24. The lower efficacy observed in study 921 may be related to inaccuracies in baseline seizure frequencies determined based on recall information. Collectively, the data suggest that most patients who take zonisamide over long periods of time do not develop tolerance to the anticonvulsant effects of the drug.
Zonisamide as monotherapy
An objective of study 921 was to reduce the dosage of concomitant AEDs, or to eliminate them altogether, while maintaining seizure control. For many patients, the dosage of concomitant AEDs was successfully reduced, and for 10 patients, concomitant AEDs were completely withdrawn for periods ranging from 6 to 140 weeks. Four of these patients achieved a seizure reduction of ≥50%, and therefore were considered responders to zonisamide monotherapy at dosages of 400-600 mg per day. Three patients remained on monotherapy through the end of the study, 140 weeks.
Safety and tolerability results
Treatment-emergent adverse events with long-term treatment were similar to those observed during short-term treatment, but their incidence declined with time. In study 920, treatment-emergent adverse events observed with short-term treatment included dizziness (27.2%), somnolence (27.2%), fatigue (23.3%), anorexia (21.4%), rhinitis (21.4%), and nausea (19.4%). With the exception of rhinitis, the percentage of patients experiencing these adverse events declined sharply with long-term treatment, with the percentage of patients reporting dizziness dropping to 12.9%; somnolence, to 7.1%; fatigue, to 3.5%; anorexia, to 7.1%, and nausea, to 10.6%. Investigators considered some of these adverse events, including fatigue, anorexia, and nausea, to be ''definitely'' attributable to zonisamide.
In study 921, adverse events most frequently reported during weeks 1-24 were somnolence, rhinitis, fatigue, nausea or vomiting, dizziness, ataxia, and anorexia. With the exception of rhinitis, the frequency with which patients reported these events declined with long-term zonisamide use. Of all reported adverse events, investigators ranked 66.6% as mild, 29.1% as moderate, and 4.2% as severe. Among adverse events rated as severe were migraine (two occurrences), anorexia (two occurrences), somnolence (three occurrences), status epilepticus (seven occurrences), and renal colic (two occurrences). About 6% of patients experienced adverse events that were considered by the investigator to be ''definitely'' attributable to zonisamide; the majority (≥75%) were classified as ''possibly'' related or ''unrelated'' to the study medication.
The incidence of clinically symptomatic kidney stones increased with long-term treatment. Among all studies, 15 of 549 patients (2.7%) had kidney stones (Table 4) , and percentages of patients affected ranged from 1.6% (912 US) to 4.9% (920). The mean study day of onset ranged from day 174 (study 912 EU EXT) to day 684 (study 912 US EXT). Most cases of renal calculi were characterized by investigators as ''possibly'' related to zonisamide treatment. Only two patients, one in study 912 US EXT and one in study 920, discontinued zonisamide treatment because of kidney stones. The rash rate among all these studies was notably low at 4%, and no serious skin-related adverse events occurred.
Discussion and conclusions
Results from placebo-controlled, short-term studies, as well as baseline-or historical-controlled, long-term studies, demonstrate that zonisamide is an effective adjunctive treatment for refractory partial-onset seizures. Zonisamide efficacy did not decline over time, suggesting that most patients do not develop tolerance to the anticonvulsant effects of zonisamide. Findings from one of the long-term studies indicate that, for some patients, zonisamide can be effective as monotherapy. Zonisamide was well-tolerated; most adverse events were mild to moderate, and their incidence declined as treatment continued. The few serious adverse events were all reversible with zonisamide dose reduction or discontinuation or the passage of time. US clinical trials show that zonisamide is a safe and effective AED for the treatment of refractory partial-onset seizures. Further studies are needed to establish monotherapy efficacy.
